A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.

@article{Hill2007ALI,
  title={A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.},
  author={J Hill and Manfred Hummel and Randall C. Starling and Jon Kobashigawa and Sergio V. Perrone and Jos{\'e} Mar{\'i}a Ariz{\'o}n and Svein Simonsen and Kamal H Abeywickrama and Christoph Bara},
  journal={Transplantation},
  year={2007},
  volume={84 11},
  pages={
          1436-42
        }
}
BACKGROUND Cytomegalovirus (CMV) infection in recipients of cardiac transplants is associated with higher rates of morbidity. A recent phase III trial showed highly significantly (P<0.001) lower CMV rates with the proliferation signal inhibitor everolimus compared to azathioprine (AZA). To better define this association, data on CMV risk factors were collected retrospectively and analyzed. METHODS Data on CMV risk factors from a multicenter phase III trial on de novo heart transplant… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Rapamycin for longevity: opinion article

VIEW 1 EXCERPT
CITES BACKGROUND